Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

629
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
629
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sarcomas developed in patients with Lynch Syndrome are enriched in pleomorphic soft-tissue sarcomas and are sensitive to immunotherapy.

European journal of cancer (Oxford, England : 1990)·2025
Same author

Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrant.

Breast cancer research : BCR·2023
Same author

The multifaceted aspects of sleep and sleep-wake disorders following stroke.

Revue neurologique·2023
Same author

Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial.

ESMO open·2023
Same author

[Apalutamide, Erleada®].

Revue medicale de Liege·2022
Same author

Recurrent or primary metastatic cervical cancer: current and future treatments.

ESMO open·2022

Related Experiment Video

Updated: Aug 18, 2025

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.4K

[CAR-T cells therapy in solid tumors : where are we now ?]

F Troisfontaine1, C Denis1, S Servais2

  • 1Service d'Oncologie, CHU Liège, Belgique.

Revue Medicale De Liege
|December 9, 2022
PubMed
Summary

Chimeric antigen receptor (CAR) T-cell therapy shows promise for blood cancers but faces challenges in solid tumors. New strategies are needed to overcome tumor heterogeneity and hostility for effective CAR-T treatment in solid tumors.

Keywords:
ImmunotherapySolid tumorsCART cells

More Related Videos

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.5K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.4K

Related Experiment Videos

Last Updated: Aug 18, 2025

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.4K
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.5K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.4K

Area of Science:

  • Immunotherapy
  • Oncology
  • Cellular Therapy

Context:

  • Chimeric antigen receptor (CAR) T-cell therapy has revolutionized hematological cancer treatment.
  • The application of CAR-T cells to solid tumors is a highly anticipated area of research.
  • Existing clinical studies highlight the potential but also the limitations of current CAR-T approaches in solid tumors.

Purpose:

  • To explore the potential of CAR-T cell therapy in treating solid tumors.
  • To identify the key obstacles hindering CAR-T cell efficacy in solid tumors.
  • To discuss the need for novel strategies to overcome these therapeutic challenges.

Summary:

  • CAR-T cells are effective against certain blood cancers, offering improved patient outcomes.
  • Solid tumors present unique challenges including antigenic heterogeneity and a hostile microenvironment.
  • These factors currently limit the effectiveness of CAR-T cell therapy in solid tumors.

Impact:

  • Advances in CAR-T cell therapy could lead to new treatment options for patients with solid tumors.
  • Overcoming current limitations may expand the application of immunotherapy.
  • Further research is crucial for developing next-generation CAR-T strategies for solid tumors.